Radiolabeled Thioflavin-T Derivative PET Imaging for the Assessment of Cardiac Amyloidosis.
Kevin Emery BoczarGary SmallAnahita TavoosiTerrence D RuddyPublished in: Current cardiology reports (2022)
F-florbetapir, -flutemetamol, and -florbetaben for the detection of cardiac amyloid. While planar imaging currently plays a large role in the workup of CA, PET imaging could play an increasing important role in the future. The quantitative abilities of novel PET tracers could theoretically allow for the serial monitoring of patients and detection of response to therapy, and the sensitive nature of the tracers could allow for even earlier disease detection. Further work with large randomized controlled trial data is needed in the development and validation of PET tracers for cardiac amyloid and represents an exciting development within the realm of nuclear cardiology.
Keyphrases
- pet imaging
- positron emission tomography
- randomized controlled trial
- loop mediated isothermal amplification
- end stage renal disease
- left ventricular
- high resolution
- label free
- real time pcr
- ejection fraction
- computed tomography
- chronic kidney disease
- stem cells
- peritoneal dialysis
- electronic health record
- pet ct
- heart failure
- systematic review
- multiple myeloma
- current status
- big data
- mass spectrometry
- machine learning
- patient reported
- cell therapy
- fluorescence imaging
- data analysis
- photodynamic therapy
- artificial intelligence
- double blind